Lv1
50 积分 2023-10-24 加入
Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis
2天前
已完结
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
2天前
已完结
Pevonedistat, a new partner for 5-azacitidine
2个月前
已关闭
Pevonedistat, a new partner for 5-azacitidine
2个月前
已关闭
Cancer incidence and mortality in China, 2022
2个月前
已完结
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease
3个月前
已完结
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
3个月前
已完结
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
3个月前
已完结
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial
3个月前
已完结
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
3个月前
已完结
皖公网安备34019202002308
